APR 0 1 2005 B

MS PETITION
PATENT

1912-0303PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

VEZINA et al.

Conf.:

Appl. No.:

09/678,303

Art Unit: 1638

Filed:

October 3, 2000

Examiner: G. Helmer

For:

PROMOTER FOR REGULATING EXPRESSION OF

FOREIGN GENES

PETITION TO WITHDRAW HOLDING OF ABANDONMENT UNDER 37 C.F.R. 1.181

SINCE REPLY WAS TIMELY FILED OR ALTERNATIVELY PETITION

FOR REVIVAL OF AN UNINTENTIONALLY ABANDONED APPLICATION

MS PETITION

April 1, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice of Abandonment mailed July 14, 2004, which issued in connection with the above-identified application, this is a Petition to withdraw the "abandonment status" of the present application, since a Reply was timely filed on January 14, 2004 or alternatively for revival of an unintentionally abandoned application.

#### 1. EVIDENCE

The Examiner assigned to the present application issued a Final Office Action on June 3, 2003 setting a date for reply to expire three (3) months from the mailing date of the Office

04/04/2005 SZEWDIE1 00000058 09678303

01 FC:2453

750.00 OP

Action (i.e., September 3, 2003). A copy of the Final Office Action is attached hereto.

1

Applicants responded with a timely filed Amendment on September 24, 2003, which included a proper petition for a one (1) month extension of time from September 3, 2003 to October 3, 2003. A copy of the Amendment is attached hereto.

The Examiner issued a Notice of Non-Responsive Amendment on December 18, 2003, a copy of which is attached hereto. The Notice indicated that the Amendment filed on October 23, 2003 was bone fide, but did not comply with revised 37 C.F.R. § 1.121. Most importantly, the Notice set a date of one (1) month or thirty (30) days from the mailing date of the notice in which to correct the non-compliant section(s) of the Amendment (i.e., January 18, 2004). The Notice further stated that extensions of this time period were available under 37 C.F.R. § 1.136(a).

In response to the Notice, Applicants filed via facsimile a compliant Amendment on January 15, 2004, which date is less than 1 month or 30 days from the mailing date of the Notice. A copy of the Amendment filed on January 15, 2004 is attached hereto. An automatically generated return receipt confirmation was received from the USPTO indicating that all five (5) pages of the Amendment were received by the USPTO on January 15, 2004. A copy of the return receipt confirmation is attached hereto.

The Examiner then issued a Notice of Abandonment erroneously dated "07/14/2002" on the cover sheet, and received by Applicants on July 22, 2004. A copy of the Notice of Abandonment is attached hereto. It is evident that the date on the cover sheet

is erroneous since paragraph 1(a) of the Notice states that a reply was received on January 15, 2004, therefore making it impossible for the Examiner to have mailed the Notice on the day before. Paragraph 1 also indicates that the Final Office Action was mailed on June 2, 2003, which is clearly erroneous (see, Final Office Action dated June 3, 2003 attached hereto).

Ĵ

In any event, paragraph 1(a) of the Notice indicates, "A reply was received on 15 January 2004..., which is after the expiration of the period for reply (including a total extension of time of 3 month(s)) which expired on 03 January 2004." Paragraph 7 indicates, "Applicant filed a responsive After Final Amendment on 15 January 2004, which is after the six-month time period following the mailing of the Final Rejection, which was mailed on 2 June 2003. This amendment was not entered."

The expiration of the period for reply set forth in the Notice of Abandonment is clearly erroneous. As noted above, the Notice of Non-Responsive Amendment set a date of one (1) month or thirty (30) days from the mailing date of the notice in which to respond. Specifically, the Notice of Non-Responsive set a date of January 18, 2004 in which to respond. The six month date of January 3, 2004 relied upon by the Examiner is irrelevant since the filing of the Amendment on September 23, 2003 tolled the six month period.

Thus, contrary to the Examiner's remarks in the Notice of Abandonment, the expiration of the period for Reply was January 18, 2004 rather than January 3, 2004. Again, Applicants duly filed a compliant Amendment on January 15, 2004, receipt of which

was acknowledged by the USPTO. For these reasons, the Notice of Abandonment is improper and should be withdrawn.

Furthermore, a Notice of Appeal is filed concurrently with this petition under separate cover. This Notice of Appeal constitutes a full response to the Final Office Action dated June 3, 2003.

In summary, as evidence of the fact that a Reply was timely filed, enclosed herewith are the following documents:

- A copy of the Final Office Action dated June 3, 2003;
- A copy of an Amendment filed on September 24, 2003;
- A copy of the Notice of Non-Compliant Reply dated December 18, 2003;
- A copy of an Amendment filed on January 15, 2004;
- A copy of the automatically generated return receipt confirmation dated January 15, 2004; and
- A copy of the Notice of Abandonment dated July 14, 2004.

It is requested that the abandonment status of the present application be immediately removed so that prosecution may resume with full consideration and entry into the record of the timely filed Reply.

It is submitted that no fees are required for filing this Petition, since the error occurred because of a mistake on the part of the U.S. Patent and Trademark Office.

#### 2. TERMINAL DISCLAIMER

The present application was filed after May 29, 2000. Therefore, a terminal disclaimer should not be required as a

condition of granting an untimely petition to withdraw the holding of abandonment, since patent term adjustment is automatically reduced under the provisions of 37 C.F.R. \$ 1.704(c)(4).

# 3. ALTERNATIVE PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. § 1.137(b)

If this Petition under 37 C.F.R. § 1.181 to withdraw the holding of abandonment is dismissed as untimely under 37 C.F.R. § 1.181(f), then the Commissioner is respectfully requested to accept this Petition under 37 C.F.R. § 1.137(b) for revival of an application for patent abandoned unintentionally.

The Petition fee of fee \$750.00 (37 C.F.R. § 1.17(m)) is attached hereto. Applicant claims small entity status. See 37 C.F.R. § 1.27. As noted above, an Amendment was previously filed on January 15, 2004. Since this utility application was filed on or after May 29, 2000, no terminal disclaimer is required.

Statement: The entire delay in filing the instant petition under 37 C.F.R. § 1.181 to withdraw the holding of abandonment from two (2) months after the mail date of the notice of abandonment until the filing of a grantable petition under 37 C.F.R. § 1.181 was unintentional.

#### 4. CONCLUSION

If the U.S. Patent Examiner has any questions regarding the above matters, please contact the undersigned at the phone number listed below.

However, if necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Gerald M. Murphy, Jr

P.O. Box 747


Falls Church VA 22040-0747

(703) 205-8000

GMM/KLR 1912-0303PUS1

#### Attachments:

- 1. Final Office Action (June 3, 2003);
- 2. Amendment (September 24, 2003);
- 3. Notice of Non-compliant Reply (December 18, 2003);
- 4. Amendment (January 15, 2004);
- 5. Return receipt confirmation (January 15, 2004); and
- 6. Notice of Abandonment (July 14, 2004)



Please find below and/or attached an Office communication concerning this application or proceeding.

	OIPE					
16	APR 0 1 2005	Application No.	Applicant(s)			
		09/678,303	VEZINA ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Georgia L. Helmer	1638			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. \$ 133).			
1) 🖂	Responsive to communication(s) filed on 26 M	<u>larch 2003</u> .				
2a)⊠		s action is non-final.				
3)□	Since this application is in condition for alloware closed in accordance with the practice under E	nce except for formal matters, pr Ex parte Quayle, 1935 C.D. 11, 4	osecution as to the merits is 53 O.G. 213.			
· _	on of Claims					
	Claim(s) 1,2,5,9 and 10 is/are pending in the a	•	er e			
1	4a) Of the above claim(s) <u>6-8</u> is/are withdrawn fi	rom consideration.	*, .			
	Claim(s) is/are allowed.					
·	6) Claim(s) <u>1,2,5,9 and 10</u> is/are rejected.					
	Claim(s) is/are objected to.					
1	Claim(s) are subject to restriction and/or on Papers	election requirement.				
9) 🗆 -	The specification is objected to by the Examiner.					
10) 🗌 🗆	The drawing(s) filed on is/are: a)☐ accept	ed or b) $\square$ objected to by the Exar	niner.			
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).			
11) 🔲 🗆	The proposed drawing correction filed on	is: a)☐ approved b)☐ disappro	ved by the Examiner.			
	If approved, corrected drawings are required in repl	* · · · · · · · · · · · · · · · · · · ·				
12)∐ 1	he oath or declaration is objected to by the Exa	miner.				
Priority u	nder 35 U.S.C. §§ 119 and 120					
13)	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	n-(d) or (f).			
a)[	☐ All b)☐ Some * c)☐ None of:					
	1. Certified copies of the priority documents	have been received.				
	2. Certified copies of the priority documents have been received in Application No					
	<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
	cknowledgment is made of a claim for domestic	· ·				
a)	☐ The translation of the foreign language prov	isional application has been rece	eived.			
	cknowledgment is made of a claim for domestic	priority under 35 U.S.C. §§ 120	and/or 121.			
Attachment		_				
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	(PTO-413) Paper No(s) atent Application (PTO-152)			
J.S. Patent and Tra PTO-326 (Rev		on Summary	Part of Paper No. 17			

Art Unit: 1638

#### **DETAILED ACTION**

### Status of the Claims

- 1. The Office acknowledges receipt of Applicants Response; dated 26 March 2003, paper number 16.
- 2. Applicant has cancelled claims 3 and 4, and amended claims 1, 2, and 5. New claims 9 and 10 have been added. Claims 1, 2, and 5-10 are pending. Claims 1, 2, 5, 9 and 10 are examined in the instant action.
- 3. This application contains claims drawn to an invention nonelected with traverse in Paper No. 12, dated 21 October 2002. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.
- 4. All rejections not addressed below have been withdrawn.
- 5. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Specification

6. The first line of the specification is objected to because it recites the serial number of the present application, while stating that this application is a continuation of the same. Correction is required.

Applicant traverses, stating primarily that the version of the application in their hands does not contain an incorporation by reference mentioning a serial number. And that Examiner must have another versions of the application. Applicant requests

Examiner to send a copy of his version so as to enable corrections to the specification.

Applicant's traversal has been considered and is unpersuasive because the language at issue is present in the Preliminary Amendment, paper No. 4, filed 1 March 2002.

Applicant has requested amending the application by replacing the paragraph line I of page 5 with an amended paragraph. However the amended "paragraph" is not a paragraph, just a part of a paragraph. This amendment is objected to under 37 CFR 121(b), which states that such amendments need to be of complete paragraphs. This amendment has not been entered and Applicant should resubmit it in proper form.

# Claim Rejections - 35 USC § 112, second paragraph

7. Claims 1,2, 5, 9, and 10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 1, "the" needs to be inserted between "consisting of" and "sequences set forth". Otherwise the claim is indefinite and reads on pieces of the complete SEQ ID Nos.

In claim 2, "the" needs to be inserted between DNA of interest by" and "presence" for clarity. Also, "presence of light" implies all light conditions of all magnitudes and wavelengths.

Art Unit: 1638

# Claim Rejections - 35 USC § 112, first paragraph

#### Enablement

8. Claims 1,2, 5, 9, and 10 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This rejection is maintained for reasons of record.

Applicant traverses, stating primarily that from the disclosure, it is shown how to prepare the expression vectors, that someone skilled in the art would easily perform the protocol described by the manufacturers specification. And that someone skilled in the art having the plasmid pGPLAS3.2 in his hands would recognize that it results from the integration of SEQ ID NO: 1 into the cloning vector pGEM/T which is a vector provided by Promega.

Applicant's traversal has been considered and is unpersuasive because no description of pGPLAS3.2 has been provided, nor is information about what DNA sequences, in what configuration, of what length, and in what orientation are present in the plasmid. Neither the specification nor the Declaration of Dr. Marc-Andre Daoust, dated 21 February 2001, provides this information.

Art Unit: 1638

Applicant traverses, stating primarily the Declaration of Dr. Marc-Andre Daoust, dated 21 February 2001, as well as the results described in the present application show that the promoter described in SEQ ID NO: 1, and fragments thereof, namely P960 and P729, which are respectively SEQ ID NO: 2 and 3, are active in inducing the transcription of the β-Glucuronidase marker genetically transformed plant cells.

Applicant's traversal has been considered and is unpersuasive because the starting materials for the experiments described in the Declaration—the specific DNA delivered, the specifics of the DNA constructs, what sequences and genes are involved, whether an expression cassette or vector is involved, are not described other than citing "the P960 deletion". No information is given on the relationship of the specifics of the Declaration to the claimed invention. What is P970? What is pGPLAS3.2? How do these relate to the claimed invention?

Applicant traverses, stating primarily that one skilled in the art will understand that Applicants do not claim plants or plants cells in which the promoters of the present invention do not work. And that also, it is well known in the art that the use of a promoter originating from one group of organism, such as dicots, can be successfully used in other groups, such as monocots or vice versa.

Applicant's traversal has been considered and is unpersuasive for reasons of record, re-cited below:

Art Unit: 1638

Applicant is not enabled for all plant cells, or for the broad scope of the claims. This is because using a promoter isolated from one species of plant would produce unpredictable results when said promoter is used to specify expression of a gene in another species of plant. Oommenn et al (1994, The Plant Cell 6:1789-1803) teach that the alfalfa isoflavone reductase promoter exhibits a different expression pattern in tobacco as compared to the expression in alfalfa. In tobacco, the alfalfa isoflavone reductase promoter expressed in vegetative tissues and in reproductive organs whereas the same construct only expressed in the root meristem, cortex and nodules of alfalfa plants (abstract).

#### Remarks

- 9. No claim is allowed.
- 10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1638

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Georgia L. Helmer whose telephone number is 703-308-7023. The examiner can normally be reached on 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on 703-306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Georgia Helmer PhD Patent Examiner Art Unit 1638

May 30, 2003

ELIZABETH F. McELWAIN PRIMARY EXAMINER GROUP 1**600** 



Filed by Facsimile (703) 308-4242

**September 24, 2003** 



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Louis-Philippe Vézina et al.

Serial No.:

09/678,303

Filing date:

October 3, 2000

Title:

PROMOTER FOR REGULATING EXPRESSION OF FOREIGN

**GENES** 

Examiner:

Helmer, Georgia L.

Tel.: (703) 308-7023

Group Art Unit:

1638

Attorney Docket:

14149-4US PM/MG/al

Agent of Applicants: Paul MARCOUX

Tel.: (418) 640-5988

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

U.S.A.

## **AMENDMENT**

Sir:

In response to the Final Official Communication of June 3, 2003, please amend the above-identified application as follows. Applicants submit concurrently herewith a petition for extension of time from September 3, 2003 to October 3, 2003 accompanied by the required fee.

#### IN THE CLAIMS

Kindly amend the claims 1, 5 and 10. Claim 2 is deleted.

- 1. (currently amended) An isolated promoter for regulating expression of foreign DNA of interest in leaves of a transgenic plant, which comprises a promoter having a sequence selected from the group consisting of the sequences set forth in SEQ ID NOS:1 to 3, wherein said promoter is operably linked to said foreign DNA of interest for expression of said foreign DNA of interest.
- 2. (currently deleted) The promoter of claim 1, wherein said promoter is activated for transcriptional expression of said foreign DNA of interest by presence of light.
- 5. (currently amended) The promoter of claim 1, wherein said plant is an dicot, a monocot or a gymnosperm alfalfa.
- 10. (currently amended) A plant cell or a plant genetically transformed with the expression vector of claim 9 for transgenic expression in leaves of foreign DNA of interest.

# IN THE SPECIFICATION

Kindly replace pages 1, 4 and 5 of the specification currently on file by the substitute pages 4 and 5 of specification enclosed herewith, on which changes relative to the immediate prior version have been marked-up.

### **REMARKS**

### IN THE CLAIMS

Claims 1, 2, 5, 9 and 10 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicants regard as the invention.

Claim 1 has been amended by introducing the word "the" between "consisting of" and "sequences set forth".

Claim 2 has been deleted from the application.

Claim 5 has been amended by limiting the group of plant to alfalfa.

Claim 10 has been amended by limiting the transgenic expression of a foreign DNA of interest to leaves of the plant cells or plants.

According to the amendments introduced into claims 1, 5 and 10, Applicants believe that the expression of a foreign DNA of interest into plants or plant cells, now being limited to leaves, is in accordance with the state of the art, particularly with Oommenn et al. (1994, The Plant Cell, vol. 6: 1789-1803) cited in the Office Action dated June 3, 2003.

No new matter has been added with the amendment.

## IN THE SPECIFICATION

In the first and second lines of the specification, the sentence "this application is a continuation application of US serial number 09/678,303 filed on October 3, 2000" has been deleted. As a petition to revive the present application number 09/678,303 has been granted on June 6, 2002, paper number 8, it is respectfully submitted that the present application be prosecuted as such, and not as a continuation of a parent application.

The Examiner has rejected the specification under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected to make and/or use the invention.

Ser. No. 09/678,303

Agent's Ref. 14149-4US PM/MG/al

A plurality of amendments were carried out in the specification by the Applicants to clarify and formalize the application.

In the paragraph bridging on line 30 of page 4 to line 9 of page 5, the disclosure was amended to replace the claim language, namely to replace the term "various" by "SEQ ID NO:2 and SEQ ID NO:3" which are described in the application and are two deletion fragments of "SEQ ID NO:1", the term SEQ ID NO:1 replaces the occurrence of "pGPlas3.2".

By limiting the deletion fragments to SEQ ID NO:2 and 3, which are fragments of SEQ ID NO:1, which themselves replaces the term pGPlas3.2, Applicants believe that the specification is now in condition enabling someone skilled in the art to carry out the invention as claimed in claim 1, 5, 9 and 10. Claim 2 was deleted from the application. No new matter has been added.

Applicants respectfully submit that the specification and claims as amended render the application in condition for allowance. Reconsideration of the objections is respectfully requested. In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned so that persecution of this application may be expedited.

Respectfully submitted,

Paul Marcoux

Registration No. 24,990

OGILVY RENAULT 1981, McGill College Suite 1600 Montreal (Quebec) Canada, H3A 2Y3

(418) 640-5988

Date: September 24, 2003

# CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Paul Marcoux, 24,990
Name of person signing certification

Signatura

September 24, 2003

Date



# PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES

This application is a continuation application of US Serial No. 09/678,303 filed on October 3, 2000.

# **BACKGROUND OF THE INVENTION**

# (a) Field of the Invention

The invention relates to a promoter for regulating expression of foreign genes in a transgenic organism, more specifically in a leaf-specific manner in transgenic plants.

# (b) Description of Prior Art

Genetic transformation of microbes have been used for more than 15 years to produce useful recombinant molecules, and applications in the pharmaceutical, cosmaceutical and dermaceutical industries are being currently exploited. This technology has expanded from microbes to plants and animals in the last ten years with the development of techniques required to adapt this general concept to complex eukaryotic organisms. Basically a gene encoding for a protein of interest or a gene encoding for an enzyme responsible for a modification of a metabolic pathway that leads to a molecule of interest, is linked in an appropriate fashion to cis-and trans-acting regulatory sequences, and transferred to a target cell where it is incorporated in the molecular machinery (in a transitory or stable fashion). The transgenic cell, or a tissue or organism regenerated from the transgenic cell will then perform transcription and translation of the transgene and therefore be enabled to accumulate the protein of interest or to perform the new metabolic reaction through the activity of the enzyme of interest.

The emerging industry of molecular farming is one of the most promising industry of the coming century. Its promise is to provide safe and renewable molecule factories for the industry. Among the applications that are currently developed are the production of low-cost monoclonal antibodies for therapeutic and diagnostic uses, the production of unlimited amounts of hormones, cytokines and other bio-active molecules for the treatment of chronicle or lethal diseases, the production of bio-safe substitutes for various blood components, the production of unlimited amounts of processing enzymes for the food and pulp industry, the production of low-cost enzymes for waste treatments, and the production of safe bio-active molecules for the cosmetic industry.

ORF of a gene, wherein said promoter is operationally located with respect to said gene for expression of said gene.

For the purpose of the present invention the following terms are defined below.

The expression "functional fragments or derivatives thereof" is intended to mean any derivative or fragment of sequences SEQ ID NOS:1-3 which allow for an equivalent level of expression of a foreign gene as the promoter of the present invention set forth in SEQ ID NOS:1-3.

# **DETAILED DESCRIPTION OF THE INVENTION**

Following is a detailed description of the method used to generate transgenic alfalfa lines that can be regulated in their expression of a reporter gene.

In this embodiment, a promoter having the sequence set forth in SEQ ID NOS:1-3 was then ligated to a reporter gene and a terminator, and this construct was inserted in suitable plant expression vectors for DNA bombardment onto alfalfa leaves and for *Agrobacterium* mediated DNA transfer as described by Desgagnés et al. (1995, *Plant Cell Tissue Organ Cult.* 42:129-140). These two DNA transfer methods were used to demonstrate that expression of the reporter gene can be modulated by light.

# **Materials and Methods**

#### **DNA** sequencing

5

10

15

20

25

30

DNA sequencing was performed as described by Sanger et al (1977, P.N.A.S. USA, 74:5643-5647).

The resulting promoters of the present invention have the sequence as set forth in SEQ ID NOS: 1 to 3.

# Construction of expression cassettes and vectors

The cassettes for expression analysis using the GUS reporter gene were assembled as follows. A promoterless GUS cassette was digested from pBI101 with HindIII and EcoRI, and was inserted into the HindIII and EcoRI sites of the pUC19 polycloning site. The resulting plasmid was named pBI201

and was used for further constructs. Various SEQ ID NO:2 and SEQ ID NO:3, two and deletion fragments of pGPlas3-2 SEQ ID NO:1, were operably transcriptionally and transitionally fused at the 5'terminus of the GUS reporter gene in pBI201 by PCR ligation, and these resulting constructs were used for transitory expression studies using DNA bombardment, Upon identification of the adequate deletion fragment, it was or subcloned into a binary plant expression vector such as pBI101 (Clonetech). These recombinant plasmids were used for stable integration through A. tumefaciens infection as described below.

10

15

25

30

# Agrobacterium-mediated DNA transfer and regeneration of transgenic lines

The recombinant plasmids were introduced into *Agrobacterium tumefaciens* strain LBA4404 by electroporation as described in Khoudi et al (1999, *Biotechnol. Bioeng.*, <u>64</u>:135-143). Selected *Agrobacterium* strains were then co-cultivated with leaf disks from genotype C5-1 for 4 days in the absence of selection pressure (kanamycin). Following this incubation period, leaf disks were washed and pampered, and then allowed to form calli onto medium B5H. Calli were then transferred for 21 days on SH medium for embryo induction and for 28 days on BOi2Y for embryo development. Torpedo-shaped embryos were removed from Boi2Y and placed on MS medium for regeneration. Kanamycin was present in all cultivation medium except for co-cultivation and regeneration on MS. This method is described in length in Desgagnés et al (1995, *Plant Cell Tissue Organ Cult.* <u>42</u>:129-140). Rooted plantlets were grown to maturity in the greenhouse.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.



# <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Applicant:

Louis-Philippe Vézina et al.

Serial No.:

09/678,303

Group Art Unit:

1638

Filed:

October 3, 2000.

Examiner:

Helmer, Georgia L.

For:

PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES

# PETITION UNDER 37 C.F.R. 1.136(a)

Commissioner for Patents, Alexandria VA 22313-1450 U.S.A.

Sir:

A one-month extension of time for response to Restriction Requirement from September 3 to October 3, 2003 is respectfully requested.

The Commissioner is hereby authorized to charge the amount of \$55.00, which covers the fee for the one-month extension of time (small entity) and is also authorized to charge any additional fees or credit any overpayment to Deposit Account No. 19-5113.

Respectfully submitted,

Date

September 24, 2003

Paul Margoux Reg. No. 24,990

OGILYY RENAULT 1981 McGill College

Suite 1600

Montreal, Quebec Canada H3A 2Y3

Tel.: (418) 640-5988



# PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES

# **BACKGROUND OF THE INVENTION**

# (a) Field of the Invention

The invention relates to a promoter for regulating expression of foreign genes in a transgenic organism, more specifically in a leaf-specific manner in transgenic plants.

# (b) Description of Prior Art

Genetic transformation of microbes have been used for more than 15 years to produce useful recombinant molecules, and applications in the pharmaceutical, cosmaceutical and dermaceutical industries are being currently exploited. This technology has expanded from microbes to plants and animals in the last ten years with the development of techniques required to adapt this general concept to complex eukaryotic organisms. Basically a gene encoding for a protein of interest or a gene encoding for an enzyme responsible for a modification of a metabolic pathway that leads to a molecule of interest, is linked in an appropriate fashion to cis-and trans-acting regulatory sequences, and transferred to a target cell where it is incorporated in the molecular machinery (in a transitory or stable fashion). The transgenic cell, or a tissue or organism regenerated from the transgenic cell will then perform transcription and translation of the transgene and therefore be enabled to accumulate the protein of interest or to perform the new metabolic reaction through the activity of the enzyme of interest.

The emerging industry of molecular farming is one of the most promising industry of the coming century. Its promise is to provide safe and renewable molecule factories for the industry. Among the applications that are currently developed are the production of low-cost monoclonal antibodies for therapeutic and diagnostic uses, the production of unlimited amounts of hormones, cytokines and other bio-active molecules for the treatment of chronicle or lethal diseases, the production of bio-safe substitutes for various blood components, the production of unlimited amounts of processing enzymes for the food and pulp industry, the production of low-cost enzymes for waste treatments, and the production of safe bio-active molecules for the cosmetic industry.

ORF of a gene, wherein said promoter is operationally located with respect to said gene for expression of said gene.

For the purpose of the present invention the following terms are defined below.

The expression "functional fragments or derivatives thereof" is intended to mean any derivative or fragment of sequences SEQ ID NOS:1-3 which allow for an equivalent level of expression of a foreign gene as the promoter of the present invention set forth in SEQ ID NOS:1-3.

# **DETAILED DESCRIPTION OF THE INVENTION**

Following is a detailed description of the method used to generate transgenic alfalfa lines that can be regulated in their expression of a reporter gene.

In this embodiment, a promoter having the sequence set forth in SEQ ID NOS:1-3 was then ligated to a reporter gene and a terminator, and this construct was inserted in suitable plant expression vectors for DNA bombardment onto alfalfa leaves and for *Agrobacterium* mediated DNA transfer as described by Desgagnés et al. (1995, *Plant Cell Tissue Organ Cult*. 42:129-140). These two DNA transfer methods were used to demonstrate that expression of the reporter gene can be modulated by light.

#### **Materials and Methods**

## **DNA** sequencing

5

10

15

20

25

30

DNA sequencing was performed as described by Sanger et al (1977, P.N.A.S. USA, 74:5643-5647).

The resulting promoters of the present invention have the sequence as set forth in SEQ ID NOS: 1 to 3.

# Construction of expression cassettes and vectors

The cassettes for expression analysis using the GUS reporter gene were assembled as follows. A promoterless GUS cassette was digested from pBI101 with HindIII and EcoRI, and was inserted into the HindIII and EcoRI sites of the pUC19 polycloning site. The resulting plasmid was named pBI201

and was used for further constructs. SEQ ID NO:2 and SEQ ID NO:3, two and deletion fragments of SEQ ID NO:1, were operably fused at the 5'terminus of the GUS reporter gene in pBI201 by PCR ligation, and resulting constructs were used for transitory expression studies using DNA bombardment or subcloned into a binary plant expression vector such as pBI101 (Clonetech). These recombinant plasmids were used for stable integration through *A. tumefaciens* infection as described below.

# Agrobacterium-mediated DNA transfer and regeneration of transgenic lines

10

15

20

25

30

The recombinant plasmids were introduced into *Agrobacterium tumefaciens* strain LBA4404 by electroporation as described in Khoudi et al (1999, *Biotechnol. Bioeng.*, <u>64</u>:135-143). Selected *Agrobacterium* strains were then co-cultivated with leaf disks from genotype C5-1 for 4 days in the absence of selection pressure (kanamycin). Following this incubation period, leaf disks were washed and pampered, and then allowed to form calli onto medium B5H. Calli were then transferred for 21 days on SH medium for embryo induction and for 28 days on BOi2Y for embryo development. Torpedo-shaped embryos were removed from Boi2Y and placed on MS medium for regeneration. Kanamycin was present in all cultivation medium except for co-cultivation and regeneration on MS. This method is described in length in Desgagnés et al (1995, *Plant Cell Tissue Organ Cult.* <u>42</u>:129-140). Rooted plantlets were grown to maturity in the greenhouse.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.







# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. 14149-4 "US" FC/118 MG 09/678,303 10/03/2000 ouis-Phillippe Vezi 5731 20988 7590 12/18/2003 EXAMINER **OGILVY RENAULT** HELMER, GEORGIA L. 1981 MCGILL COLLEGE AVENUE wabey Ochy Renautt **SUITE 1600** ART UNIT PAPER NUMBER McGill College MONTREAL, QC H3A2Y3 1638 CANADA DATE MAILED: 12/18/2003 DUE ON JUN 18 2004 9/

Please find below and/or attached an Office communication concerning this application or proceeding.







# UNITED STATES DEPA TMENT OF COMMERCE U.S. Patent and Traden...ark Office Address: COMMISSIONER FOR PATENTS

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR I PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
			EXAMINER	
			· ·	
			ART UNIT	PAPER
	,			33

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents** 

09/678,303

See attached Notice of Non-Responsive Amendment.

# Notice of Non-Responsive Amendment

1. The reply filed on 23 October 2003 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): All amendments filed on or after the effective date of 30 July 2003 must comply with revised 37 CFR 1.121. See MPEP 714.03 (Rev. 1, Feb 2003). See Final Rule: Changes To Implement Electronic Maintenance of Official Patent Application Records (68 Fed. Reg. 38611 June 30, 2003, posted on the Office's website at: <a href="http://www.uspto.gov/web/patents/ifw/">http://www.uspto.gov/web/patents/ifw/</a> with related information. The noncompliant section(s) will have to be corrected and the entire corrected section(s) resubmitted within a set period.

Since the above-mentioned reply appears to be *bona fide*, applicant is given

ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

2. Any inquiry concerning this communication or earlier communications from the \$71-273-0796 examiner should be directed to Georgia L. Helmer whose telephone number is \$703-308-7023. Note that Examiner's phone number will change to 571-272-0796 as of 6 January 2004. The examiner can normally be reached on 8:30 - 5:00.

Art Unit: 1638

Page 3

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on 703-306-3218. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Georgia Helmer PhD
Patent Examiner
Transgenic Plants, Art unit 1638
November 26, 2003

ELIZABETH F. McELWAIN PRIMARY EXAMINER GROUP 1600

COPY



Filed by Facsimile (703) 872-9306 January 15, 2004

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Louis-Philippe Vézina et al.

Serial No.:

09/678,303

Filing date:

October 3, 2000

Title:

PROMOTER FOR REGULATING EXPRESSION OF FOREIGN

**GENES** 

Examiner:

Helmer, Georgia L.

Tel.: (571) 272-0796

SPE:

Nelson, Amy

Tel.: (703) 306-3218

Group Art Unit:

1638

Attorney Docket:

14149-4US PM/MG/al

Agent of Applicants: Isabelle CHABOT

Tel.: (418) 640-5174

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

U.S.A.

#### **AMENDMENT**

Sir:

In response to the Official Communication of December 18, 2003, containing a Notice of Non-Responsive Amendment, please amend the above-identified application as follows.

Applicants apologize for the error in formatting the last reply of October 23, 2003 to the final office action of June 3, 2003. The present amendment presents the same content as our reply of October 23, 2003 but the amendment format is hereby corrected.

### IN THE CLAIMS

Kindly amend claims 1, 5 and 10. Claim 2 is deleted.

1. (currently amended) An isolated promoter for regulating expression of foreign DNA of interest in leaves of a transgenic plant, which comprises a promoter having a sequence selected from the group consisting of the sequences set forth in SEQ ID NOS:1 to 3, wherein said promoter is operably linked to said foreign DNA of interest for expression of said foreign DNA of interest.

- 2. (currently deleted)
- 3. (previously deleted)
- 4. (previously deleted)
- 5. (currently amended) The promoter of claim 1, wherein said plant is an dicot, a monocot or a gymnosperm alfalfa.
- 6. (nonelected) A method of regulating expression of foreign genes in transgenic organisms, comprising the steps of: preparing a transgenic organism using an expression construct consisting of at least a promoter of claim 1, and an ORF of a gene, wherein said promoter is operationally located with respect to said gene for expression of said gene.
- 7. (nonelected) The method of claim 6, wherein said organism is a plant.
- 8. (nonelected) The method of claim 7, wherein said plant is a dicot, a monocot or a gymnosperm.
- 9. (original) An expression vector comprising a promoter as defined in claim 1.
- 10. (currently amended) A plant cell or a plant genetically transformed with the expression vector of claim 9 for transgenic expression in leaves of foreign DNA of interest.

Ser. No. 09/678,303

#### IN THE SPECIFICATION

Kindly amend the specification as follows:

At page 1, delete the paragraph starting at line 2, namely

This application is a continuation application of US Serial No. 09/678,303 filed on October 3, 2000.

At page 5, replace the paragraph starting at line 1 by:

and was used for further constructs. SEQ ID NO:2 and SEQ ID NO:3, two and deletion fragments of SEQ ID NO:1, were operably fused at the 5'terminus of the GUS reporter gene in pBI201 by PCR ligation, and resulting constructs were used for transitory expression studies using DNA bombardment or subcloned into a binary plant expression vector such as pBI101 (Clonetech). These recombinant plasmids were used for stable integration through *A. tumefaciens* infection as described below.

#### <u>REMARKS</u>

## IN THE CLAIMS

Claims 1, 2, 5, 9 and 10 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicants regard as the invention.

Claim 1 has been amended by introducing the word "the" between "consisting of" and "sequences set forth".

Claim 2 has been deleted from the application.

Claim 5 has been amended by limiting the group of plant to alfalfa.

Claim 10 has been amended by limiting the transgenic expression of a foreign DNA of interest to leaves of the plant cells or plants.

According to the amendments introduced into claims 1, 5 and 10, Applicants believe that the expression of a foreign DNA of interest into plants or plant cells, now being limited to leaves, is in accordance with the state of the art, particularly with Oommenn et al. (1994, The Plant Cell, vol. 6: 1789-1803) cited in the Office Action dated June 3, 2003.

No new matter has been added with the amendment.

#### IN THE SPECIFICATION

In the first and second lines of the specification, the sentence "this application is a continuation application of US serial number 09/678,303 filed on October 3, 2000" has been deleted. As a petition to revive the present application number 09/678,303 has been granted on June 6, 2002, paper number 8, it is respectfully submitted that the present application be prosecuted as such, and not as a continuation of a parent application.

The Examiner has rejected the specification under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected to make and/or use the invention.

A plurality of amendments were carried out in the specification by the Applicants to clarify and formalize the application.

In the paragraph bridging on line 30 of page 4 to line 9 of page 5, the disclosure was amended to replace the claim language, namely to replace the term "various" by "SEQ ID NO:2 and SEQ ID NO:3" which are described in the application and are two deletion fragments of "SEQ ID NO:1", the term SEQ ID NO:1 replaces the occurrence of "pGPlas3.2".

By limiting the deletion fragments to SEQ ID NO:2 and 3, which are fragments of SEQ ID NO:1, which themselves replaces the term pGPlas3.2, Applicants believe that the specification is now in condition enabling someone skilled in the art to carry out the invention as claimed in claim 1, 5, 9 and 10. Claim 2 was deleted from the application. No new matter has been added.

Applicants respectfully submit that the specification and claims as amended render the application in condition for allowance. Reconsideration of the objections is respectfully requested. In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned so that persecution of this application may be expedited.

Respectfully submitted,

By:

Isabelle CHABOT, Reg. No. P-55,764 Provisionally registered patent agent Customer Number 020988

OGILVY RENAULT 1981, McGill College, Suite 1600 Montreal (Quebec) Canada, H3A 2Y3 (418) 640-5174

Date: January 15, 2004

#### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Isabelle CHABOT (Reg. No. P-55,764)

Name of person signing certification

Signature Chalot

January 15, 2004

Date

Ser. No. 09/678,303

Agent's Ref. 14149-4US PM/MG/al

RAPPORT ÉMISSION \*\*\*\*\*\*\*\*\*\*\*\*\*

ÉMISSION OK

N° ÉM/RÉC

TÉLÉPHONE CONNEX

SOUS-ADRESSE

IDENT CONNEXION

h DÉBUT

DURÉE

PGS. TRANSMISES

RÉSULTAT

2590

#19217038729306

15/01 11:18

01'05

5 OK

Filed by Facsimile (703) 872-9306 January 15, 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Louis-Philippe Vézina et al.

Serial No.:

09/678,303

Filing date:

October 3, 2000

Title:

PROMOTER FOR REGULATING EXPRESSION OF FOREIGN

**GENES** 

Examiner:

Helmer, Georgia L.

Tel.: (571) 272-0796

SPE:

Nelson, Amy

Tel.: (703) 306-3218

Group Art Unit:

1638

Attorney Docket:

14149-4US PM/MG/al

Agent of Applicants: Isabelle CHABOT

Tel.: (418) 640-5174

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

U.S.A.

#### **AMENDMENT**



USPTO 1/15/2004 11:23 AM PAGE 1/001 Fax Server 5: Auto-xeply fax to 418 640 00 COMPANY:

**Auto-Reply Facsimile Transmission** 





TO:

Fax Sender at 418 640 1500

Fax Information

Date Received: Total Pages:


1/15/2004 11:15:30 AM [Eastern Standard Time]

5 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received Cover Page =====>

Ø 001 15/01 2004 11:18 FAX 418 640 1500 Filed by Facsimile (703) 872-9306 January 15, 2004 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Applicants: Louis-Philippe Vézina et al. Serial No.: 09/678.303 Filing date: October 3, 2000 PROMOTER FOR REGULATING EXPRESSION OF FOREIGN Examiner: Helmer, Georgia L. Tel.: (571) 272-0796 Nelson, Amy SPE: Tel.: (703) 306-3218 Group Art Unit: 1638 14149-4US PM/MG/a) Attorney Docket: Agent of Applicants: Isabelle CHABOT Tel.: (418) 640-5174 Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450 AMENDMENT Sir. In response to the Official Communication of December 18, 2003, containing a Notice of Non-Responsive Amendment, please amend the above-identified application as follows. Applicants apologize for the error in formatting the last reply of October 23, 2003 to the final office action of June 3, 2003. The present amendment presents the same content as our reply of October 23, 2003 but the amendment format is hereby corrected. PAGE 1.5\* RCVD AT 1/15/2004 11:15/20 AM (Eastern Standard Time)\* SVR:USPTO-EFXRF-1/10\* DNIS:8/729306\* CSID:418 640 1500 \* DURÁTION (mm-ss):01-34



Please find below and/or attached an Office communication concerning this application or proceeding.



	Application No.	Applicant(s)				
Notice of Abandanmant	09/678,303	VEZINA ET AL.				
Notice of Abandonment	Examiner	Art Unit				
	Georgia L. Helmer	1638				
The MAILING DATE of this communication app	·					
This application is abandoned in view of:						
Applicant's failure to timely file a proper reply to the Offic     (a) ☑ A reply was received on 15 January 2004 (with a Cerexpiration of the period for reply (including a total exte	tificate of Mailing or Transmission da					
(b) ☑ A proposed reply was received on <u>26 September 200</u> final rejection.	23, but it does not constitute a proper	reply under 37 CFR 1.113 (a) to the				
(A proper reply under 37 CFR 1.113 to a final rejection consists only of. (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).						
(c) ☑ A reply was received on <u>15 January 2004</u> but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).						
(d) ☐ No reply has been received.						
2. Applicant's failure to timely pay the required issue fee an from the mailing date of the Notice of Allowance (PTOL-8		the statutory period of three months				
(a) The issue fee and publication fee, if applicable, was), which is after the expiration of the statutory p Allowance (PTOL-85).						
(b) The submitted fee of \$ is insufficient. A balance	e of \$ is due.					
The issue fee required by 37 CFR 1.18 is \$	The publication fee, if required by 37	CFR 1.18(d), is \$				
(c) ☐ The issue fee and publication fee, if applicable, has n	ot been received.					
3. Applicant's failure to timely file corrected drawings as requestional Allowability (PTO-37).	uired by, and within the three-month p	period set in, the Notice of				
(a) Proposed corrected drawings were received on after the expiration of the period for reply.	_(with a Certificate of Mailing or Tran	nsmission dated), which is				
(b) ☐ No corrected drawings have been received.						
4. The letter of express abandonment which is signed by the the applicants.	e attorney or agent of record, the ass	ignee of the entire interest, or all of				
5. The letter of express abandonment which is signed by an 1.34(a)) upon the filing of a continuing application.	attorney or agent (acting in a repres	entative capacity under 37 CFR				
6. The decision by the Board of Patent Appeals and Interfer of the decision has expired and there are no allowed clair		se the period for seeking court review				
7. 🖾 The reason(s) below:						
Applicant filed a responsive After Final Amendment following the mailing of the Final Rejection, which w	on 15 January 2004, which is is as mailed on 2 June 2003. This	after the six-month time period amendment was not entered.				
Alloren		ELIZABETH F. McELWAIN PRIMARY EXAMINER GROUP 1800				
Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdra minimize any negative effects on patent term.	w the holding of abandonment under 37					
U.S. Patent and Trademark Office	f Abandonment	Part of Paper No. 77				

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

# IMAGES ARE BEST AVAILABLE COPY.

OTHER: \_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.